Learning Objectives:

1. Recognize the role of STING in ultra-rare rheumatic diseases including SAVI and COPA syndrome.

2. Describe the role of RIG-I deficiency in antiviral immunity and hemophagocytic lymphohistiocytosis.

3. Explain how disease-causing mutant proteins can be utilized in whole-genome CRISPR/Cas9 screens to identify novel therapeutic targets.

Session date: 
Tuesday, April 6, 2021 - 8:30am to 9:30am
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Jonathan Miner, M.D., Ph.D.